Amphotericin B Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region & Competition, 2021-2031F

The Global Amphotericin B Market is forecast to grow from USD 561.05 Million in 2025 to USD 733.15 Million by 2031, exhibiting a 4.56% CAGR. Amphotericin B, a broad-spectrum polyene antifungal antibiotic administered intravenously, is vital for treating severe, life-threatening systemic fungal infections such as mucormycosis and cryptococcal meningitis. Market expansion is largely propelled by the escalating global prevalence of invasive mycoses among immunocompromised populations, including organ transplant recipients and oncology patients undergoing chemotherapy, and the increasing resistance to azole-based therapies. Approximately 6.5 million individuals are estimated to be affected annually by life-threatening fungal diseases, emphasizing the critical need for effective antifungal treatments. This demand is intensified by the rising incidence of invasive fungal infections, particularly those caused by multi-drug resistant strains like Candida auris, which recorded 4,514 cases in the U.S. in 2023, alongside a sustained baseline demand from pathologies such as the over 2.1 million annual cases of invasive aspergillosis globally. However, a major impediment to market growth is the severe nephrotoxicity associated with conventional deoxycholate formulations, necessitating the use of considerably safer but substantially more expensive lipid-based alternatives, which consequently limit accessibility and adoption in low-to-middle-income healthcare systems.

Market Driver

The rising incidence of invasive fungal infections, particularly those caused by multi-drug resistant strains, is a primary catalyst propelling the demand for Amphotericin B. Pathogens like Candida auris increasingly exhibit resistance to first-line azole and echinocandin therapies, prompting healthcare providers to revert to Amphotericin B for its broad fungicidal activity and low resistance rates. This trend is intensified by the growing prevalence of hospital-acquired infections among immunocompromised groups, with, for instance, clinical cases of multi-drug resistant Candida auris in the U.S. reaching 4,514 in 2023. Additionally, the market is sustained by the sheer volume of specific fungal pathologies, with over 2.1 million people globally estimated to develop invasive aspergillosis annually. Concurrently, advancements in lipid-based drug delivery systems are reshaping the market by directly addressing the nephrotoxicity limitations of conventional formulations. Pharmaceutical developers are actively engineering novel oral and lipid-nanocrystal mechanisms to maintain the drug's efficacy while significantly improving its safety profile and patient compliance. These innovations are crucial for expanding the drug's utility beyond acute hospital settings into step-down therapies, as demonstrated by the treatment of 24 patients with severe invasive fungal infections using an oral lipid-nanocrystal formulation in a compassionate use program. These technological progressions are vital for unlocking new market segments, promising to reduce the heavy economic burden associated with hospitalization for traditional intravenous administration.

Market Challenge

The prohibitive cost of lipid-based formulations represents a critical economic barrier that severely constrains the Global Amphotericin B Market, particularly in high-burden, low-to-middle-income countries. While lipid complex and liposomal variants offer a necessary clinical alternative to the nephrotoxic conventional deoxycholate, their premium pricing structure restricts widespread adoption in regions where invasive fungal infections are most endemic. This price disparity creates a bifurcated market where the safer, higher-value products are financially inaccessible to the public healthcare systems that require them the most, effectively capping revenue growth by limiting the addressable market to wealthy developed nations. Consequently, the gap between clinical necessity and economic feasibility prevents the market from capitalizing on the rising volume of cases in developing economies. This lack of accessibility directly correlates with adverse patient outcomes and lost commercial opportunity, as invasive fungal diseases were estimated to result in approximately 3.8 million deaths globally in 2025, a mortality burden heavily concentrated in resource-limited settings where consistent access to less toxic, high-grade antifungal pharmacotherapies remains elusive due to acquisition costs. This inability to penetrate high-need markets due to pricing pressures remains a primary drag on global industry momentum.

Market Trends

Following the patent expiration of major branded liposomal products, the market is experiencing a surge in the approval and commercialization of cost-effective generic versions, significantly altering the competitive landscape. This expansion of generic and biosimilar therapeutics is rapidly increasing accessibility in cost-sensitive regions, allowing healthcare systems to transition away from nephrotoxic conventional formulations without incurring the prohibitive costs of originator brands. This trend is underscored by robust growth in sales, such as a 10.1% year-over-year increase in certain US formulation sales, reflecting rising market penetration of these non-branded alternatives. Concurrently, clinical treatment protocols are increasingly moving toward single high-dose or short-course regimens, particularly for Cryptococcal Meningitis and Visceral Leishmaniasis, to reduce hospitalization time and cumulative toxicity. This evolution in the standard of care is reshaping volume demand and packaging requirements, driving a shift from prolonged daily infusions to concentrated, high-value dosing schedules. However, widespread implementation still faces inertia as providers slowly adapt to these updated guidelines; a review of recent clinical management practices revealed that only 14% of infectious disease physicians had fully adopted a specific single-dose liposomal Amphotericin B regimen (AMBITION-cm protocol), indicating a significant opportunity for market development as professional consensus consolidates around these efficient delivery models.

Key Market Players

• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• Sun Pharmaceutical Industries Ltd.
• Cipla Limited
• Mylan N.V.
• Xellia Pharmaceuticals ApS
• Fresenius Kabi AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.

Report Scope

In this report, the Global Amphotericin B Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Amphotericin B Market, By Sales Channel

• Direct
• Indirect

Amphotericin B Market, By End Use

• Systemic Fungal Infections
• Candidiasis
• Aspergillosis
• Mucormycosis
• Leishmaniasis
• Others

Amphotericin B Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Amphotericin B Market.

Available Customizations:

Global Amphotericin B Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).